Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

A recent medical trial could help deliver the first daily weight loss pill capable of cutting down obesity as effectively as ...

For those looking to jumpstart their weight journey or finally reach their fitness goals, one option that is the center of ...

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

Eli Lilly, the maker of Ozempic, has developed a weight loss pill that could work as well. The new weight loss pill, orforglipron, is a once-daily oral GLP-1 receptor agonist that is designed to lower ...

During oral arguments, the defendants contended that the plaintiffs could not support their allegations that Novo Nordisk and ...

Weight loss drugs, already a relatively new and revolutionary concept within the medical industry, are shaking things up once again. Move over Ozempic, pharmaceutical giant Eli Lilly […] ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.